Business Wire

Esmark Inc. Announces All-Cash Public Offer for U.S. Steel Shares

Share

Esmark, Inc. announced today a voluntary public cash and exchange offer for all issued and outstanding shares in U.S. Steel Corporation (NYSE: X) (“U.S. Steel”) for $35 USD per share. The initial offer period runs from August 14, 2023, to November 30, 2023, and may be extended. Completion of the Offer is expected in Q4 2023, subject to regulatory and antitrust clearances.

“With more than 40 years of steel industry experience, and as a former executive and statutory representative of U.S. Steel, I have significant intimacy with the steel business in the U.S. and around the globe,” said James P. Bouchard, Chairman & CEO of Esmark, Inc., Executive Committee Member of the American Steel Institute and the European Steel Association (Eurofer). Bouchard is Forever Chairman & CEO of Esmark/Wheeling Pittsburg Steel (Ticker Symbol: ESMK). Under Bouchard’s helm, Esmark/Wheeling Pittsburg was the fourth largest steel company in the U.S.

Bouchard continued, “This is an exciting time as the entire American Steel industry is restructuring, and with Esmark’s long-standing history of excellence, we are anxious to continue to grow and we’re well positioned to come in and operate.”

Founded in 1901, United States Steel Corporation is a steel producer serving the automotive, construction, appliance, energy, containers, and packaging industries.

Prior to founding Esmark, Bouchard was Vice President-Commercial for U.S. Steel in Europe, residing in Kosice, Slovak Republic. He was a member of the executive team that U.S. Steel dispatched to Kosice after having acquired the Slovakian National Steel Company (VSZ).

Bouchard was widely credited with the successful commercial restructuring, implementation, and subsequent growth strategy of the company's European sales, marketing, strategic planning, and customer service initiatives, and was ultimately responsible for the company's commercial operations in 42 countries. The Kosice operation became the most profitable steel asset owned by U.S. Steel at that time.

Esmark Steel Group, a wholly owned subsidiary of Esmark, Inc., is one of the United States’ leading processors and distributors of value-added flat-rolled steel and the third-largest U.S. producer of tin plate steel. We offer the products, services and innovations to help our customers gain and sustain the competitive edge in their industries.

More About Mr. Bouchard:

Bouchard is the Founder, Chairman, and Chief Executive Officer of Esmark Inc. and its predecessor and controlling shareholder, the Bouchard Group, which was formed in 1995 with an initial $500 investment and is still 100 percent privately owned by Bouchard. Over the years, the Bouchard Group has grown and evolved into a diversified VC Investment Holding Company with strategic assets engaged in the Industrial, Energy, Technology, Real Estate, Commodities industries, and Youth Sports and Development.

Esmark and the Bouchard Group's roots are firmly planted in the steel industry. In 2003, the company acquired two Chicago area steel services companies, Electric Coating Technologies and Sun Steel. The acquisitions served as the genesis for Bouchard to found and bring the legendary Fortune 50 Esmark name and brand back to life when he formed the new Esmark Inc. II in 2003 to focus on steel company acquisitions. Bouchard subsequently transferred his Bouchard Group steel assets and capitalized the new Esmark II in 2004.

In 2007, he and his management team successfully completed the first hostile tender/reverse merger in the history of the United States with the merger of Wheeling Pittsburgh Steel Corporation (formerly NASDAQ: WPSC) and Esmark II. Bouchard served as Chairman and Chief Executive Officer of the iconic Wheeling-Pittsburgh Steel Corporation in 2006 before completing the merger with Esmark in 2007. He then built Esmark II into a publicly traded (formerly NASDAQ: ESMK), $3 billion company before it was ultimately sold to OAO Severstal for $1.3 billion in August 2008.

Bouchard, through the Bouchard Group, later repurchased the Esmark name, trademark, and intellectual property from OAO Severstal and brought the Esmark name and respective brand back to life for a third time when he founded Esmark Inc. III in October of 2008 with no revenue and one employee. The Bouchard Group is Esmark's III controlling shareholder. Esmark III is one of the nation's fastest growing companies with assets in excess of $200 million. With its diverse portfolio of companies, Esmark III generates more than $500 million in revenue annually.

During his 30-year career, Bouchard has served on the Board of Directors of a number steel industry organizations and companies, including the American Iron and Steel Institute (AISI) in Washington, D.C. He also formerly served on the C.D.E. committee for Eurofer in Brussels, Belgium, and the Board of Directors for Wheeling-Nisshan Steel Corporation and Ohio Coatings Company.

In addition to serving as Chairman of the Board and CEO of Esmark Inc., Esmark Steel Group, Inc., and the Bouchard Group, he is Co-Chairman of Ohio Coatings Company (OCC) in Yorkville, Ohio. Bouchard also currently serves as a member of the Board of Trustees at Loyola University-Chicago and Robert Morris University. Bouchard is a Dartmouth University Tuck School of Business Entrepreneurial Management Instructor. As well, he is on the Board of Directors for several Pittsburgh-based organizations including FC Pittsburgh Soccer Club, the Imani Christian Academy, the Quaker Valley Hockey Association, and the City of Champions for Haiti humanitarian group.

Bouchard is also the Chairman and majority owner of Johnstown Sports Partners LLC and majority owner of the NAHL's Johnstown Tomahawks Hockey Team in Johnstown, PA.

Bouchard is the recipient of numerous industry and philanthropic awards for his accomplishments and contributions. In 2005, he was nominated and named as an Illinois Finalist of the prestigious Ernst & Young Entrepreneur of the Year Award. In March 2006, the Association of Steel Distributors bestowed their highest honor on him as "Steel Man of the Year." In 2007, he was inducted into the Hinsdale Central High School Hall of Fame, the youngest inductee in the history of the school. He is a recipient of the Hinsdale Central, James Carmanani Award. Bouchard was also honored by Loyola University as the 2007-08 recipient of the Chicago Damen Award for distinguished alumni. And in 2010, he was named a Paul Harris Fellow by Rotary International for his humanitarian relief efforts during the aftermath of the earthquake in Haiti. In 2012, Bouchard was named Sewickley, Pennsylvania's "Man of the Year" for his ongoing support of multiple children's charities, youth sports and development programs, and other humanitarian organizations throughout Western Pennsylvania and Pittsburgh's inner city. Also in 2012, Bouchard was named a finalist for "CEO of the Year" by global publishing concern Platts International and subsidiary Steel Business Briefing for his years of leadership, vision, and innovation in the steel industry. He is a part of the Pittsburgh City of Champions Hall of Fame and the Quaker Valley Hall of Fame.

James P. Bouchard family, along with the Esmark family of companies, continue to be tireless supporters of a wide range of educational, family health and wellness, youth sports and recreation programs in Pennsylvania, Illinois, and in Haiti including the Helen E. Bouchard Scholarship Award (totaling $500,000 to 75 recipients), with donations totaling more than $10 million since 2003.

About Esmark, Inc.

Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com
(708) 898-5550

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye